Zydus Receives Final Approval From The USFDA For Lamotrigine Extended-Release Tablets

Zydus Cadila has received final approval from the USFDA to market Lamotrigine Extended-Release Tablets USP in the strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg. (US RLD: Lamictal XR®)

This medication is indicated for the treatment of certain types of seizures and will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 283 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.262.9 as compared to the previous close of Rs. 267.1. The total number of shares traded during the day was 59878 in over 1476 trades.

The stock hit an intraday high of Rs. 273.25 and intraday low of 260.85. The net turnover during the day was Rs. 16071114.-Equity Bulls